EQT and KKR have advanced to a concrete stage of due diligence on a potential take-private of the molecular diagnostics company, arriving just as Qiagen's chief executive is set to hand over the role.
Qiagen's flirtation with private ownership has moved beyond early speculation. EQT and KKR have each been granted access to a data room as part of an advanced round of take-private discussions, according to people familiar with the process. Data-room access typically indicates a sale process has narrowed to a smaller set of serious bidders rather than a broad canvass of interested parties.
What remains missing is any public indication of price. No offer figure, exclusivity arrangement, or bidding deadline has been disclosed by either sponsor or by Qiagen. Data-room access does not commit either firm to a bid, and it says nothing about how the two are likely to value a business spanning molecular diagnostics instruments, consumables, and bioinformatics software.
The process is unfolding alongside a separate scheduled corporate event: Qiagen's chief executive transition takes effect . No evidence links the planned leadership change to the takeover talks, and the two should not be read as connected without further support. Still, an incoming management team inheriting an active sale process faces a different backdrop than one starting with a clean slate.
Advent International has also been mentioned in connection with Qiagen's strategic review, but its role remains unconfirmed. It is neither confirmed to be participating in the data-room stage alongside EQT and KKR nor confirmed to have been excluded.
For a company of Qiagen's scale, two identified sponsors at the data-room stage marks meaningful progress toward a possible transaction, but it remains several steps short of a signed deal. The next developments that would materially change the picture are a formal bid, a signed agreement, a withdrawal, or confirmation of which sponsors remain in the process.